+

WO2002070004A3 - Immunogenes et vaccins ainsi que leur preparation et leur utilisation - Google Patents

Immunogenes et vaccins ainsi que leur preparation et leur utilisation Download PDF

Info

Publication number
WO2002070004A3
WO2002070004A3 PCT/GB2002/000975 GB0200975W WO02070004A3 WO 2002070004 A3 WO2002070004 A3 WO 2002070004A3 GB 0200975 W GB0200975 W GB 0200975W WO 02070004 A3 WO02070004 A3 WO 02070004A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
immune response
papillomavirus
vaccines
response against
Prior art date
Application number
PCT/GB2002/000975
Other languages
English (en)
Other versions
WO2002070004A2 (fr
Inventor
Julian Kingdon Hickling
Terry O'neill
Rienk Offringa
Der Burg Sjoerd Van
Original Assignee
Xenova Res Ltd
Univ Leiden Medical Ct
Julian Kingdon Hickling
Terry O'neill
Rienk Offringa
Der Burg Sjoerd Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Res Ltd, Univ Leiden Medical Ct, Julian Kingdon Hickling, Terry O'neill, Rienk Offringa, Der Burg Sjoerd Van filed Critical Xenova Res Ltd
Priority to AU2002236065A priority Critical patent/AU2002236065A1/en
Priority to BR0207899A priority patent/BR0207899A/pt
Priority to EP02702541A priority patent/EP1399182A2/fr
Priority to JP2002569176A priority patent/JP2004522789A/ja
Publication of WO2002070004A2 publication Critical patent/WO2002070004A2/fr
Publication of WO2002070004A3 publication Critical patent/WO2002070004A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des immunogènes et des vaccins ainsi que leur préparation et leur utilisation. L'invention concerne, en particulier, des immunogènes de combinaison comprenant un immunogène d'activation et de rappel dirigé contre les antigènes protéiques de papillomavirus, et leur utilisation en vue de stimuler une réponse immunitaire contre ces papillomavirus, notamment une réponse immunitaire prophylactique ou thérapeutique contre une infection due au papillomavirus humain (HPV).
PCT/GB2002/000975 2001-03-07 2002-03-07 Immunogenes et vaccins ainsi que leur preparation et leur utilisation WO2002070004A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002236065A AU2002236065A1 (en) 2001-03-07 2002-03-07 Papillomavirus vaccines
BR0207899A BR0207899A (pt) 2001-03-07 2002-03-07 Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente
EP02702541A EP1399182A2 (fr) 2001-03-07 2002-03-07 Immunogenes et vaccins ainsi que leur preparation et leur utilisation
JP2002569176A JP2004522789A (ja) 2001-03-07 2002-03-07 乳頭腫ウイルスワクチン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105606.8 2001-03-07
GB0105606A GB0105606D0 (en) 2001-03-07 2001-03-07 Immunogens and vaccines and their preparation and use

Publications (2)

Publication Number Publication Date
WO2002070004A2 WO2002070004A2 (fr) 2002-09-12
WO2002070004A3 true WO2002070004A3 (fr) 2003-12-31

Family

ID=9910150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000975 WO2002070004A2 (fr) 2001-03-07 2002-03-07 Immunogenes et vaccins ainsi que leur preparation et leur utilisation

Country Status (6)

Country Link
EP (1) EP1399182A2 (fr)
JP (1) JP2004522789A (fr)
AU (1) AU2002236065A1 (fr)
BR (1) BR0207899A (fr)
GB (1) GB0105606D0 (fr)
WO (1) WO2002070004A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013472A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
EP2199301A1 (fr) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Polypeptides immunogénétiques comportant un polypeptide recombinant et polypeptide L2 ou son fragment
WO2017211886A1 (fr) 2016-06-07 2017-12-14 Deutsches Krebsforschungszentrum Amélioration de l'immunogénicité des peptides l2 de hpv
JP7454320B2 (ja) * 2018-02-22 2024-03-22 ターンストーン リミテッド パートナーシップ アジュバントとしての腫瘍溶解性ウイルス

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (fr) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Vecteurs viraux recombinants codant pour des proteines du papillomavirus humain
WO1996026277A1 (fr) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
WO2000011140A1 (fr) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Techniques permettant d'augmenter l'immunite des muqueuses par l'intermediaire d'un premier vaccin systemique et d'un rappel mucosal
WO2001014416A2 (fr) * 1999-08-25 2001-03-01 Merck & Co., Inc. Genes synthetiques humains du virus de papillome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (fr) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Vecteurs viraux recombinants codant pour des proteines du papillomavirus humain
WO1996026277A1 (fr) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
WO2000011140A1 (fr) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Techniques permettant d'augmenter l'immunite des muqueuses par l'intermediaire d'un premier vaccin systemique et d'un rappel mucosal
WO2001014416A2 (fr) * 1999-08-25 2001-03-01 Merck & Co., Inc. Genes synthetiques humains du virus de papillome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN C-H ET AL: "Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 19, April 2000 (2000-04-01), pages 2015 - 2022, XP004202497, ISSN: 0264-410X *
MURAKAMI MASARU ET AL: "Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.", CANCER RESEARCH, vol. 59, no. 6, 15 March 1999 (1999-03-15), pages 1184 - 1187, XP002238464, ISSN: 0008-5472 *
RAMSHAW I A ET AL: "The prime - boost strategy: Exciting prospects for improved vaccination", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 4, April 2000 (2000-04-01), pages 163 - 165, XP002179214, ISSN: 0167-5699 *
VAN DER BURG S H ET AL: "Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 27, 14 June 2001 (2001-06-14), pages 3652 - 3660, XP004241783, ISSN: 0264-410X *

Also Published As

Publication number Publication date
GB0105606D0 (en) 2001-04-25
AU2002236065A1 (en) 2002-09-19
EP1399182A2 (fr) 2004-03-24
BR0207899A (pt) 2004-10-19
JP2004522789A (ja) 2004-07-29
WO2002070004A2 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
EP1246644A4 (fr) Reponse immunitaire cellulaire au papillomavirus humain induite par utilisation de compositions peptidiques et d'acide nucleique
WO2004075829A3 (fr) Vaccin contre la grippe contenant un adjuvant
WO1999010375A3 (fr) Vaccin
WO2003028632A3 (fr) Mise au point d'un vaccin preventif contre l'infection par filovirus chez les primates
WO2003028760A3 (fr) Vaccin
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
WO2004014418A3 (fr) Composition vaccinale
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
AU4322996A (en) Variants of human papilloma virus antigens
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
WO2002036790A3 (fr) Vecteur de virus grippal destine a l'infection de cellules dendritiques
WO2001054719A3 (fr) Nouvelle utilisation
WO2002013857A8 (fr) Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
WO2005089164A3 (fr) Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2003038047A3 (fr) Transcriptase inverse de la telomerase humaine utilisee comme antigene tumoral de restriction de classe ii
WO2000062801A3 (fr) Nouvelles compositions
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
WO2003063899A3 (fr) Adjuvant de vaccin
WO2002087494A3 (fr) Nouveau vaccin
WO2003066094A3 (fr) Nouveau vaccin
WO2003059385A3 (fr) Vaccin contre le vih et procede d'utilisation
WO2004037175A3 (fr) Compositions et methodes pour traiter une maladie a mediation par le papillomavirus humain (hpv)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002702541

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002569176

Country of ref document: JP

Ref document number: PA/A/2003/007982

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 028074173

Country of ref document: CN

Ref document number: 1249/KOLNP/2003

Country of ref document: IN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002702541

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002702541

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载